Hedging on Hype
Four major pharmaceutical rivals—Pfizer, AstraZeneca, Merck, and Teva—formed a joint venture called AION Labs in 2020 to explore AI applications in drug discovery. The collaboration allowed these competitors to share the high costs and risks associated with testing emerging AI technologies.
Why it matters
This unique alliance demonstrates how traditional industry competitors are increasingly pooling resources to navigate the high-stakes integration of AI into R&D processes.
How Four Pharma Rivals Used One Venture Studio to Test-Drive Every AI Trend of the Decade
Objective analysis of a business partnership and industry trends.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in